Stem Cell Banking Market By Service Type (Storage, Testing & Processing, and Collection); By Source (Umbilical Cord, Placenta, Amniotic Fluid, Bone Marrow, Others); By Medical Condition (Cancer (Leukaemias, Lymphomas, Etc.), Non Malignant Blood Disorders (Anaemias, Hereditary Bone Marrow Failure Syndromes, Etc.), Immune Disorder (Severe Combined Immune Deficiency (SCID), Inherited Immune System Disorders, etc.), Metabolic Disorders (Leukodystrophy Disorders, Mucopolysaccharidosis (MPS) Storage Diseases, Etc.) and Others); By Application (Disease Treatment & Tissue Regeneration, Clinical Research, and Personalized Banking Applications); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Stem cell banking is defined as the process of collecting, processing and storing stem cells that have the potential of offering lifesaving treatments. Collected stem cells are safely kept for future use in therapies and regenerative medicine. As stem cells can develop into many different types of blood and tissue cell, they can regenerate and protect the body from within. In cases where a disease or medical condition affects cell tissue, stem cell therapies can repair not only the damaged tissue, but also the organs as they treat the ailments.
Many factors are driving the global stem cell banking market but the most important factor is rising average human life expectancy. The average human life expectancy has increased in most parts of the world due to the advancements in medical science. Human aging is still associated with several diseases. Geriatric population is increasing in many countries and the demand for stem cell banking as well as stem cell therapy is anticipated to accelerate in these countries, thereby influencing the growth of global stem cell banking market over the forecast period. Regulatory authorities as well as non-governmental organizations (NGO), across both developed countries and developing countries, are taking initiatives for spreading awareness amongst consumers about the therapeutic potentials of stem cells, which is also driving the growth of global stem cell banking market. Increasing fertility rates has led to a rise in the number of child-births and children all over the world. Hence, lucrative opportunities for preserving the umbilical cord of infants which contains hematopoietic (blood) stem cells, is anticipated to contribute towards the growth of global stem cell banking market over the future years.
Investments towards advancement in stem cell banking, treatment of immunity-related disorders, neutropenias, and severe combined immune deficiency (SCID) are estimated to showcase significant growth opportunities for global stem cell banking market over the period of next eight years. Cryo-cell has enabled many families to access treatment for child requiring 100% genetically matched cells for themselves. This has been made possible due to preserving cord blood and cord tissue at birth. Through stem cells banking, cells become partial match for parents and blood-related siblings during treatment. In the times of coronavirus, stem cells therapy is being adopted for treating those parts which are damaged due to virus. In order to treat coronavirus, bone marrow from people who recovered from this diseases are helpful and some medical institutions who offer stem cell banking are also offering bone marrow banking in the lines of stem cells banking.
Although, stem cells are often considered as an effective alternative form of therapies, there have been debates over the use of stem cells in the development of therapies. Questions about ethical and legal issues create a need for regulatory framework. Some countries have strict restrictions on stem cell banking and stem cell treatment. Hence, expensive medical procedures and regulatory complications are hindering the growth of global stem cell banking market.
Absolute Market Insights reports, the global stem cell banking market is likely to grow at 10% CAGR during the 2021-2029 period, and reach a valuation of US$ 15089.64 Mn by 2029.
Global Stem Cell Banking Market Revenue & Forecast, (US$ Million), 2015 – 2029
Service Type Outlook:
By service types, this research report from Absolute Markets Insights on the global stem cell banking market covers storage, testing & processing, and collection. In 2020, the testing & processing segment held the largest market share among the three segments.
During the forecast period, storage and collection services are estimated to register highest growth rate. Due to COVID-19 pandemic, people are increasingly inclined to save their healthy stem cells so that they can be used in case any infection destroy the cells in their body. The collection of umbilical cord blood is usually done from new born babies. It is done in hospitals immediately after the babies are born. After the qualified doctors and nurses collect it, the umbilical cord blood is stored into the special kits provided. The collected samples are then delivered to laboratories and arrangements are made that the samples arrive in laboratories within 24 hours. Once the collected units arrive at storage facilities, the scientists and doctors conducting research and experiments, examine the cord blood carefully to determine whether the samples meet the standards of cryopreservation. Cryopreservation includes visual checking, measuring temperature upon arrival, weighing, examining hospital collection records of the delivered cord blood and verifying the maternal blood sample along with client information so that the customer profiles can be established. Due to advancements in medical technology, there are different methods for sample collection and preservation being adopted across medical facilities. With collection becoming easy and preservation of samples becoming safer, the segments are expected to witness substantial growth rate over the forecast period.
Application Outlook:
The application segment in the global stem cell banking market in this report has been broadly segmented into disease treatment & tissue regeneration, clinical research, and personalized banking applications. In 2020, disease treatment & tissue regeneration category held the largest market share. During the forecast period, personalized banking applications is anticipated to witness fastest growth rate owing to the increasing use of technology, including hardware, software and applications in the medical sector.
Source Outlook:
The source-based segmentation in the global stem cell banking market covers umbilical cord, placenta, amniotic fluid, bone marrow, and others. In 2020, umbilical cord segment held the largest market share.
During the forecast period, the placenta segment is expected to account for the highest CAGR. Human placenta offers a renewable source of cell replacement for many therapies including anti-aging therapy and regeneration medicine. It is also useful for the treatment of various neurological disorders and immunity-related disorders. Placental stem cell therapy is expected to offer effective treatment for many ailments that were believed to be untreatable until recently. The human placenta and cord blood are rich sources of hematopoietic progenitor cells and hematopoietic stem cells (HSCs). HSCs give rise to all the blood cell types including myeloid (basophils, dendritic cells, eosinophils, erythrocytes, macrophages & monocytes, megakaryocytes/platelets, and neutrophils) cells and lymphoid lineage (B-cells, NK cells, and T-cells) cells.
Medical Condition Outlook:
On the basis of medical condition, the global stem cell banking market is classified into cancer (leukaemias, lymphomas, etc.), non-malignant blood disorders (anaemias, hereditary bone marrow failure syndromes, etc.), immune disorder (severe combined immune deficiency (SCID), inherited immune system disorders, etc.), metabolic disorders (leukodystrophy disorders, mucopolysaccharidosis (MPS) storage diseases, etc.), and others. Cancer accounted for the highest market share in 2020.
During the forecast period, non-malignant blood disorders (anaemias, hereditary bone marrow failure syndromes, etc.) segment is anticipated to witness fastest growth. Stem cell treatment has been effective in the treatment of many anaemias such as aplastic anaemia, congenital dyserythropoietic anaemia, Fanconi’s anaemia, and paroxysmal nocturnal hemoglobinuria. It can also cure hereditary bone marrow failure syndromes such as diamond blackfan syndrome, dyskeratosis congenita, pearson’s syndrome, and shwachman diamond syndrome. Many inherited red cell abnormalities such as beta thalassemia major/Cooley’s anaemia, pure red cell aplasia, and sickle cell anaemia are also treatable through adoption of adequate treatment modalities.
Region Outlook:
In 2020, North America held the largest share in the global stem cell banking market. During the forecast period, Asia Pacific region is estimated to witness highest CAGR, due to increasing growth of medical sector in countries like Japan, South Korea, India, China, and Singapore. Asian hospitals, especially those in China and India, are offering world-class healthcare services at prices cheaper than those in Europe and North America. Rise in the older population along with surge in prevalence of chronic diseases that older people are more prone to is contributing towards the region’s growth in the global market.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of stem cell banking market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global stem cell banking market are CBR Systems, Inc., Cell Care, CHA Biotech, CordBank New Zealand, Cordlife, Cryo-Cell, CryoHoldco, Cryoviva India, CSG-BIO, Global Cord Blood Corporation., LifeCell International Pvt. Ltd., ReeLabs Pvt. Ltd., Regrow Biosciences Pvt Ltd., Smart Cells International Ltd., Stem Med Pte Ltd, StemCyte, ViaCord and Vita 34 Inc. amongst others.
Global Stem Cell Banking Market:
By Service Type
- Storage
- Testing and Processing
- Collection
By Source
- Umbilical Cord
- Placenta
- Amniotic Fluid
- Bone Marrow
- Others
By Medical Condition
- Cancer (Leukaemias, Lymphomas, Etc.)
- Non Malignant Blood Disorders (Anaemias, Hereditary Bone Marrow Failure Syndromes, Etc.)
- Immune Disorder (Severe Combined Immune Deficiency (SCID), Inherited Immune System Disorders, etc.)
- Metabolic Disorders (Leukodystrophy Disorders, Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
- Others
By Application
- Disease Treatment & Tissue Regeneration
- Clinical Research
- Personalized Banking Applications
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Stem Cell Banking Market
6. Market Synopsis: Stem
Cell Banking Market
7. Stem Cell Banking Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Stem Cell Banking Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Stem Cell Banking Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Stem Cell Banking Market
8. Global Stem Cell Banking Market Analysis and Forecasts, 2021
– 2029
8.1. Overview
8.1.1. Global
Stem Cell Banking Market Revenue (US$ Mn)
8.2. Global
Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Service Type
8.2.1. Storage
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2020
8.2.1.3. Market Forecast, 2021 - 2029
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2020
8.2.1.5.1.2. Market
Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2020
8.2.1.5.2.2. Market
Forecast, 2021 - 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2020
8.2.1.5.3.2. Market
Forecast, 2021 - 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2020
8.2.1.5.4.2. Market
Forecast, 2021 - 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2020
8.2.1.5.5.2. Market
Forecast, 2021 - 2029
8.2.2. Testing
and Processing
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2020
8.2.2.3. Market Forecast, 2021 - 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2020
8.2.2.5.1.2. Market
Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2020
8.2.2.5.2.2. Market
Forecast, 2021 - 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2020
8.2.2.5.3.2. Market
Forecast, 2021 - 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2020
8.2.2.5.4.2. Market
Forecast, 2021 - 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2020
8.2.2.5.5.2. Market
Forecast, 2021 - 2029
8.2.3. Collection
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2020
8.2.3.3. Market Forecast, 2021 - 2029
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2020
8.2.3.5.1.2. Market
Forecast, 2021 - 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2020
8.2.3.5.2.2. Market
Forecast, 2021 - 2029
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2020
8.2.3.5.3.2. Market
Forecast, 2021 - 2029
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2020
8.2.3.5.4.2. Market
Forecast, 2021 - 2029
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2020
8.2.3.5.5.2. Market
Forecast, 2021 - 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By
Service Type
9. Global Stem Cell Banking Market Analysis and Forecasts, 2021
– 2029
9.1. Overview
9.2. Global
Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Source
9.2.1. Umbilical
Cord
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2020
9.2.1.3. Market Forecast, 2021 - 2029
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2020
9.2.1.5.1.2. Market
Forecast, 2021 - 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2020
9.2.1.5.2.2. Market
Forecast, 2021 - 2029
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2020
9.2.1.5.3.2. Market
Forecast, 2021 - 2029
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2020
9.2.1.5.4.2. Market
Forecast, 2021 - 2029
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2020
9.2.1.5.5.2. Market
Forecast, 2021 - 2029
9.2.2. Placenta
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2020
9.2.2.3. Market Forecast, 2021 - 2029
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2020
9.2.2.5.1.2. Market
Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2020
9.2.2.5.2.2. Market
Forecast, 2021 - 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2020
9.2.2.5.3.2. Market
Forecast, 2021 - 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2020
9.2.2.5.4.2. Market
Forecast, 2021 - 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2020
9.2.2.5.5.2. Market
Forecast, 2021 - 2029
9.2.3. Amniotic
Fluid
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2020
9.2.3.3. Market Forecast, 2021 - 2029
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2020
9.2.3.5.1.2. Market
Forecast, 2021 - 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2020
9.2.3.5.2.2. Market
Forecast, 2021 - 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2020
9.2.3.5.3.2. Market
Forecast, 2021 - 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2020
9.2.3.5.4.2. Market
Forecast, 2021 - 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2020
9.2.3.5.5.2. Market
Forecast, 2021 - 2029
9.2.4. Bone
Marrow
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2020
9.2.4.3. Market Forecast, 2021 - 2029
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2020
9.2.4.5.1.2. Market
Forecast, 2021 - 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2020
9.2.4.5.2.2. Market
Forecast, 2021 - 2029
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2020
9.2.4.5.3.2. Market
Forecast, 2021 - 2029
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2020
9.2.4.5.4.2. Market
Forecast, 2021 - 2029
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2020
9.2.4.5.5.2. Market
Forecast, 2021 - 2029
9.2.5. Others
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2020
9.2.5.3. Market Forecast, 2021 - 2029
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2020
9.2.5.5.1.2. Market
Forecast, 2021 - 2029
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2020
9.2.5.5.2.2. Market
Forecast, 2021 - 2029
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2020
9.2.5.5.3.2. Market
Forecast, 2021 - 2029
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2020
9.2.5.5.4.2. Market
Forecast, 2021 - 2029
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2020
9.2.5.5.5.2. Market
Forecast, 2021 - 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Source
10. Global Stem Cell Banking Market Analysis and Forecasts, 2021
– 2029
10.1. Overview
10.2. Global
Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Medical Condition
10.2.1. Cancer
(Leukaemias, Lymphomas, Etc.)
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2020
10.2.1.5.1.2. Market
Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2020
10.2.1.5.2.2. Market
Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2020
10.2.1.5.3.2. Market
Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2020
10.2.1.5.4.2. Market
Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2020
10.2.1.5.5.2. Market
Forecast, 2021 - 2029
10.2.2. Non
Malignant Blood Disorders (Anaemias, Hereditary Bone Marrow Failure Syndromes,
Etc.)
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2020
10.2.2.5.1.2. Market
Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2020
10.2.2.5.2.2. Market
Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2020
10.2.2.5.3.2. Market
Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2020
10.2.2.5.4.2. Market
Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2020
10.2.2.5.5.2. Market
Forecast, 2021 - 2029
10.2.3. Immune
Disorder (Severe Combined Immune Deficiency (SCID), Inherited Immune System
Disorders, etc.)
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2020
10.2.3.5.1.2. Market
Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2020
10.2.3.5.2.2. Market
Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2020
10.2.3.5.3.2. Market
Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2020
10.2.3.5.4.2. Market
Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2020
10.2.3.5.5.2. Market
Forecast, 2021 - 2029
10.2.4. Metabolic
Disorders (Leukodystrophy Disorders, Mucopolysaccharidosis (MPS) Storage
Diseases, Etc.)
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2020
10.2.4.3. Market Forecast, 2021 - 2029
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2020
10.2.4.5.1.2. Market
Forecast, 2021 - 2029
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2020
10.2.4.5.2.2. Market
Forecast, 2021 - 2029
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2020
10.2.4.5.3.2. Market
Forecast, 2021 - 2029
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2020
10.2.4.5.4.2. Market
Forecast, 2021 - 2029
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2020
10.2.4.5.5.2. Market
Forecast, 2021 - 2029
10.2.5. Others
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 - 2020
10.2.5.3. Market Forecast, 2021 - 2029
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market
Estimation, 2015 - 2020
10.2.5.5.1.2. Market
Forecast, 2021 - 2029
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 - 2020
10.2.5.5.2.2. Market
Forecast, 2021 - 2029
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market
Estimation, 2015 - 2020
10.2.5.5.3.2. Market
Forecast, 2021 - 2029
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 - 2020
10.2.5.5.4.2. Market
Forecast, 2021 - 2029
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market
Estimation, 2015 - 2020
10.2.5.5.5.2. Market
Forecast, 2021 - 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By
Medical Condition
11. Global Stem Cell Banking Market Analysis and Forecasts, 2021
– 2029
11.1. Overview
11.2. Global
Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Application
11.2.1. Disease
Treatment and Tissue Regeneration
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2020
11.2.1.3. Market Forecast, 2021 - 2029
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 - 2020
11.2.1.5.1.2. Market
Forecast, 2021 - 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 - 2020
11.2.1.5.2.2. Market
Forecast, 2021 - 2029
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 - 2020
11.2.1.5.3.2. Market
Forecast, 2021 - 2029
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 - 2020
11.2.1.5.4.2. Market
Forecast, 2021 - 2029
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 - 2020
11.2.1.5.5.2. Market
Forecast, 2021 - 2029
11.2.2. Clinical
Research
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2020
11.2.2.3. Market Forecast, 2021 - 2029
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 - 2020
11.2.2.5.1.2. Market
Forecast, 2021 - 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 - 2020
11.2.2.5.2.2. Market
Forecast, 2021 - 2029
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 - 2020
11.2.2.5.3.2. Market
Forecast, 2021 - 2029
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 - 2020
11.2.2.5.4.2. Market
Forecast, 2021 - 2029
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 - 2020
11.2.2.5.5.2. Market
Forecast, 2021 - 2029
11.2.3. Personalized
Banking Applications
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 - 2020
11.2.3.3. Market Forecast, 2021 - 2029
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 - 2020
11.2.3.5.1.2. Market
Forecast, 2021 - 2029
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 - 2020
11.2.3.5.2.2. Market
Forecast, 2021 - 2029
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 - 2020
11.2.3.5.3.2. Market
Forecast, 2021 - 2029
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 - 2020
11.2.3.5.4.2. Market
Forecast, 2021 - 2029
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 - 2020
11.2.3.5.5.2. Market
Forecast, 2021 - 2029
11.3. Key
Segment for Channeling Investments
11.3.1. By
Application
12. North America Stem Cell Banking Market Analysis and
Forecasts, 2021 - 2029
12.1. Overview
12.1.1. North
America Stem Cell Banking Market Revenue (US$ Mn)
12.2. North
America Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Service
Type
12.2.1. Storage
12.2.2. Testing
and Processing
12.2.3. Collection
12.3. North
America Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Source
12.3.1. Umbilical
Cord
12.3.2. Placenta
12.3.3. Amniotic
Fluid
12.3.4. Bone
Marrow
12.3.5. Others
12.4. North
America Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Medical
Condition
12.4.1. Cancer
(Leukaemias, Lymphomas, Etc.)
12.4.2. Non
Malignant Blood Disorders (Anaemias, Hereditary Bone Marrow Failure Syndromes,
Etc.)
12.4.3. Immune
Disorder (Severe Combined Immune Deficiency (SCID), Inherited Immune System
Disorders, etc.)
12.4.4. Metabolic
Disorders (Leukodystrophy Disorders, Mucopolysaccharidosis (MPS) Storage
Diseases, Etc.)
12.4.5. Others
12.5. North
America Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Application
12.5.1. Disease
Treatment and Tissue Regeneration
12.5.2. Clinical
Research
12.5.3. Personalized
Banking Applications
12.6. North
America Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Service Type
12.6.1.1.1. Storage
12.6.1.1.2. Testing and Processing
12.6.1.1.3. Collection
12.6.1.2. U.S Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Source
12.6.1.2.1. Umbilical Cord
12.6.1.2.2. Placenta
12.6.1.2.3. Amniotic Fluid
12.6.1.2.4. Bone Marrow
12.6.1.2.5. Others
12.6.1.3. U.S Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Medical Condition
12.6.1.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
12.6.1.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
12.6.1.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
12.6.1.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
12.6.1.3.5. Others
12.6.1.4. U.S Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Application
12.6.1.4.1. Disease Treatment and Tissue Regeneration
12.6.1.4.2. Clinical Research
12.6.1.4.3. Personalized Banking Applications
12.6.2. Canada
12.6.2.1. Canada Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
12.6.2.1.1. Storage
12.6.2.1.2. Testing and Processing
12.6.2.1.3. Collection
12.6.2.2. Canada Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
12.6.2.2.1. Umbilical Cord
12.6.2.2.2. Placenta
12.6.2.2.3. Amniotic Fluid
12.6.2.2.4. Bone Marrow
12.6.2.2.5. Others
12.6.2.3. Canada Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
12.6.2.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
12.6.2.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
12.6.2.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
12.6.2.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
12.6.2.3.5. Others
12.6.2.4. Canada Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.2.4.1. Disease Treatment and Tissue Regeneration
12.6.2.4.2. Clinical Research
12.6.2.4.3. Personalized Banking Applications
12.6.3. Mexico
12.6.3.1. Mexico Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
12.6.3.1.1. Storage
12.6.3.1.2. Testing and Processing
12.6.3.1.3. Collection
12.6.3.2. Mexico Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
12.6.3.2.1. Umbilical Cord
12.6.3.2.2. Placenta
12.6.3.2.3. Amniotic Fluid
12.6.3.2.4. Bone Marrow
12.6.3.2.5. Others
12.6.3.3. Mexico Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
12.6.3.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
12.6.3.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
12.6.3.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
12.6.3.3.4. Metabolic Disorders (Leukodystrophy Disorders, Mucopolysaccharidosis
(MPS) Storage Diseases, Etc.)
12.6.3.3.5. Others
12.6.3.4. Mexico Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.3.4.1. Disease Treatment and Tissue Regeneration
12.6.3.4.2. Clinical Research
12.6.3.4.3. Personalized Banking Applications
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Stem Cell Banking Market Revenue (US$
Mn) and Forecasts, By Service Type
12.6.4.1.1. Storage
12.6.4.1.2. Testing and Processing
12.6.4.1.3. Collection
12.6.4.2. Rest of North America Stem Cell Banking Market Revenue (US$
Mn) and Forecasts, By Source
12.6.4.2.1. Umbilical Cord
12.6.4.2.2. Placenta
12.6.4.2.3. Amniotic Fluid
12.6.4.2.4. Bone Marrow
12.6.4.2.5. Others
12.6.4.3. Rest of North America Stem Cell Banking Market Revenue (US$
Mn) and Forecasts, By Medical Condition
12.6.4.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
12.6.4.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
12.6.4.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
12.6.4.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
12.6.4.3.5. Others
12.6.4.4. Rest of North America Stem Cell Banking Market Revenue (US$
Mn) and Forecasts, By Application
12.6.4.4.1. Disease Treatment and Tissue Regeneration
12.6.4.4.2. Clinical Research
12.6.4.4.3. Personalized Banking Applications
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Service Type
12.7.3. By
Source
12.7.4. By
Medical Condition
12.7.5. By
Application
13. Europe Stem Cell Banking Market Analysis and Forecasts, 2021
- 2029
13.1. Overview
13.1.1. Europe
Stem Cell Banking Market Revenue (US$ Mn)
13.2. Europe
Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Service Type
13.2.1. Storage
13.2.2. Testing
and Processing
13.2.3. Collection
13.3. Europe
Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Source
13.3.1. Umbilical
Cord
13.3.2. Placenta
13.3.3. Amniotic
Fluid
13.3.4. Bone
Marrow
13.3.5. Others
13.4. Europe
Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Medical Condition
13.4.1. Cancer
(Leukaemias, Lymphomas, Etc.)
13.4.2. Non
Malignant Blood Disorders (Anaemias, Hereditary Bone Marrow Failure Syndromes,
Etc.)
13.4.3. Immune
Disorder (Severe Combined Immune Deficiency (SCID), Inherited Immune System
Disorders, etc.)
13.4.4. Metabolic
Disorders (Leukodystrophy Disorders, Mucopolysaccharidosis (MPS) Storage
Diseases, Etc.)
13.4.5. Others
13.5. Europe
Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Application
13.5.1. Disease
Treatment and Tissue Regeneration
13.5.2. Clinical
Research
13.5.3. Personalized
Banking Applications
13.6. Europe
Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
13.6.1.1.1. Storage
13.6.1.1.2. Testing and Processing
13.6.1.1.3. Collection
13.6.1.2. France Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
13.6.1.2.1. Umbilical Cord
13.6.1.2.2. Placenta
13.6.1.2.3. Amniotic Fluid
13.6.1.2.4. Bone Marrow
13.6.1.2.5. Others
13.6.1.3. France Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
13.6.1.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
13.6.1.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
13.6.1.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
13.6.1.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
13.6.1.3.5. Others
13.6.1.4. France Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.1.4.1. Disease Treatment and Tissue Regeneration
13.6.1.4.2. Clinical Research
13.6.1.4.3. Personalized Banking Applications
13.6.2. The UK
13.6.2.1. The UK Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
13.6.2.1.1. Storage
13.6.2.1.2. Testing and Processing
13.6.2.1.3. Collection
13.6.2.2. The UK Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
13.6.2.2.1. Umbilical Cord
13.6.2.2.2. Placenta
13.6.2.2.3. Amniotic Fluid
13.6.2.2.4. Bone Marrow
13.6.2.2.5. Others
13.6.2.3. The UK Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
13.6.2.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
13.6.2.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
13.6.2.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
13.6.2.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
13.6.2.3.5. Others
13.6.2.4. The UK Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.2.4.1. Disease Treatment and Tissue Regeneration
13.6.2.4.2. Clinical Research
13.6.2.4.3. Personalized Banking Applications
13.6.3. Spain
13.6.3.1. Spain Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Service Type
13.6.3.1.1. Storage
13.6.3.1.2. Testing and Processing
13.6.3.1.3. Collection
13.6.3.2. Spain Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Source
13.6.3.2.1. Umbilical Cord
13.6.3.2.2. Placenta
13.6.3.2.3. Amniotic Fluid
13.6.3.2.4. Bone Marrow
13.6.3.2.5. Others
13.6.3.3. Spain Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Medical Condition
13.6.3.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
13.6.3.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
13.6.3.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
13.6.3.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
13.6.3.3.5. Others
13.6.3.4. Spain Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Application
13.6.3.4.1. Disease Treatment and Tissue Regeneration
13.6.3.4.2. Clinical Research
13.6.3.4.3. Personalized Banking Applications
13.6.4. Germany
13.6.4.1. Germany Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
13.6.4.1.1. Storage
13.6.4.1.2. Testing and Processing
13.6.4.1.3. Collection
13.6.4.2. Germany Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
13.6.4.2.1. Umbilical Cord
13.6.4.2.2. Placenta
13.6.4.2.3. Amniotic Fluid
13.6.4.2.4. Bone Marrow
13.6.4.2.5. Others
13.6.4.3. Germany Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
13.6.4.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
13.6.4.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
13.6.4.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
13.6.4.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
13.6.4.3.5. Others
13.6.4.4. Germany Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.4.4.1. Disease Treatment and Tissue Regeneration
13.6.4.4.2. Clinical Research
13.6.4.4.3. Personalized Banking Applications
13.6.5. Italy
13.6.5.1. Italy Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Service Type
13.6.5.1.1. Storage
13.6.5.1.2. Testing and Processing
13.6.5.1.3. Collection
13.6.5.2. Italy Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Source
13.6.5.2.1. Umbilical Cord
13.6.5.2.2. Placenta
13.6.5.2.3. Amniotic Fluid
13.6.5.2.4. Bone Marrow
13.6.5.2.5. Others
13.6.5.3. Italy Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Medical Condition
13.6.5.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
13.6.5.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
13.6.5.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
13.6.5.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
13.6.5.3.5. Others
13.6.5.4. Italy Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Application
13.6.5.4.1. Disease Treatment and Tissue Regeneration
13.6.5.4.2. Clinical Research
13.6.5.4.3. Personalized Banking Applications
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
13.6.6.1.1. Storage
13.6.6.1.2. Testing and Processing
13.6.6.1.3. Collection
13.6.6.2. Nordic Countries Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
13.6.6.2.1. Umbilical Cord
13.6.6.2.2. Placenta
13.6.6.2.3. Amniotic Fluid
13.6.6.2.4. Bone Marrow
13.6.6.2.5. Others
13.6.6.3. Nordic Countries Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
13.6.6.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
13.6.6.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
13.6.6.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
13.6.6.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
13.6.6.3.5. Others
13.6.6.4. Nordic Countries Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.6.4.1. Disease Treatment and Tissue Regeneration
13.6.6.4.2. Clinical Research
13.6.6.4.3. Personalized Banking Applications
13.6.6.5. Nordic Countries Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
13.6.7.1.1. Storage
13.6.7.1.2. Testing and Processing
13.6.7.1.3. Collection
13.6.7.2. Benelux Union Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
13.6.7.2.1. Umbilical Cord
13.6.7.2.2. Placenta
13.6.7.2.3. Amniotic Fluid
13.6.7.2.4. Bone Marrow
13.6.7.2.5. Others
13.6.7.3. Benelux Union Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
13.6.7.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
13.6.7.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
13.6.7.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
13.6.7.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
13.6.7.3.5. Others
13.6.7.4. Benelux Union Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.7.4.1. Disease Treatment and Tissue Regeneration
13.6.7.4.2. Clinical Research
13.6.7.4.3. Personalized Banking Applications
13.6.7.5. Benelux Union Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
13.6.8.1.1. Storage
13.6.8.1.2. Testing and Processing
13.6.8.1.3. Collection
13.6.8.2. Rest of Europe Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
13.6.8.2.1. Umbilical Cord
13.6.8.2.2. Placenta
13.6.8.2.3. Amniotic Fluid
13.6.8.2.4. Bone Marrow
13.6.8.2.5. Others
13.6.8.3. Rest of Europe Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
13.6.8.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
13.6.8.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
13.6.8.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
13.6.8.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
13.6.8.3.5. Others
13.6.8.4. Rest of Europe Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.8.4.1. Disease Treatment and Tissue Regeneration
13.6.8.4.2. Clinical Research
13.6.8.4.3. Personalized Banking Applications
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By
Service Type
13.7.3. By
Source
13.7.4. By
Medical Condition
13.7.5. By
Application
14. Asia Pacific Stem Cell Banking Market Analysis and Forecasts,
2021 - 2029
14.1. Overview
14.1.1. Asia
Pacific Stem Cell Banking Market Revenue (US$ Mn)
14.2. Asia
Pacific Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Service
Type
14.2.1. Storage
14.2.2. Testing
and Processing
14.2.3. Collection
14.3. Asia
Pacific Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Source
14.3.1. Umbilical
Cord
14.3.2. Placenta
14.3.3. Amniotic
Fluid
14.3.4. Bone
Marrow
14.3.5. Others
14.4. Asia
Pacific Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Medical
Condition
14.4.1. Cancer
(Leukaemias, Lymphomas, Etc.)
14.4.2. Non
Malignant Blood Disorders (Anaemias, Hereditary Bone Marrow Failure Syndromes,
Etc.)
14.4.3. Immune
Disorder (Severe Combined Immune Deficiency (SCID), Inherited Immune System
Disorders, etc.)
14.4.4. Metabolic
Disorders (Leukodystrophy Disorders, Mucopolysaccharidosis (MPS) Storage
Diseases, Etc.)
14.4.5. Others
14.5. Asia
Pacific Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Application
14.5.1. Disease
Treatment and Tissue Regeneration
14.5.2. Clinical
Research
14.5.3. Personalized
Banking Applications
14.6. Asia
Pacific Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Service Type
14.6.1.1.1. Storage
14.6.1.1.2. Testing and Processing
14.6.1.1.3. Collection
14.6.1.2. China Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Source
14.6.1.2.1. Umbilical Cord
14.6.1.2.2. Placenta
14.6.1.2.3. Amniotic Fluid
14.6.1.2.4. Bone Marrow
14.6.1.2.5. Others
14.6.1.3. China Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Medical Condition
14.6.1.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
14.6.1.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
14.6.1.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
14.6.1.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
14.6.1.3.5. Others
14.6.1.4. China Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Application
14.6.1.4.1. Disease Treatment and Tissue Regeneration
14.6.1.4.2. Clinical Research
14.6.1.4.3. Personalized Banking Applications
14.6.2. Japan
14.6.2.1. Japan Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Service Type
14.6.2.1.1. Storage
14.6.2.1.2. Testing and Processing
14.6.2.1.3. Collection
14.6.2.2. Japan Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Source
14.6.2.2.1. Umbilical Cord
14.6.2.2.2. Placenta
14.6.2.2.3. Amniotic Fluid
14.6.2.2.4. Bone Marrow
14.6.2.2.5. Others
14.6.2.3. Japan Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Medical Condition
14.6.2.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
14.6.2.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
14.6.2.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
14.6.2.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
14.6.2.3.5. Others
14.6.2.4. Japan Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Application
14.6.2.4.1. Disease Treatment and Tissue Regeneration
14.6.2.4.2. Clinical Research
14.6.2.4.3. Personalized Banking Applications
14.6.3. India
14.6.3.1. India Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Service Type
14.6.3.1.1. Storage
14.6.3.1.2. Testing and Processing
14.6.3.1.3. Collection
14.6.3.2. India Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Source
14.6.3.2.1. Umbilical Cord
14.6.3.2.2. Placenta
14.6.3.2.3. Amniotic Fluid
14.6.3.2.4. Bone Marrow
14.6.3.2.5. Others
14.6.3.3. India Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Medical Condition
14.6.3.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
14.6.3.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
14.6.3.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
14.6.3.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
14.6.3.3.5. Others
14.6.3.4. India Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Application
14.6.3.4.1. Disease Treatment and Tissue Regeneration
14.6.3.4.2. Clinical Research
14.6.3.4.3. Personalized Banking Applications
14.6.4. New
Zealand
14.6.4.1. New Zealand Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
14.6.4.1.1. Storage
14.6.4.1.2. Testing and Processing
14.6.4.1.3. Collection
14.6.4.2. New Zealand Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
14.6.4.2.1. Umbilical Cord
14.6.4.2.2. Placenta
14.6.4.2.3. Amniotic Fluid
14.6.4.2.4. Bone Marrow
14.6.4.2.5. Others
14.6.4.3. New Zealand Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
14.6.4.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
14.6.4.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
14.6.4.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
14.6.4.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
14.6.4.3.5. Others
14.6.4.4. New Zealand Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.4.4.1. Disease Treatment and Tissue Regeneration
14.6.4.4.2. Clinical Research
14.6.4.4.3. Personalized Banking Applications
14.6.5. Australia
14.6.5.1. Australia Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
14.6.5.1.1. Storage
14.6.5.1.2. Testing and Processing
14.6.5.1.3. Collection
14.6.5.2. Australia Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
14.6.5.2.1. Umbilical Cord
14.6.5.2.2. Placenta
14.6.5.2.3. Amniotic Fluid
14.6.5.2.4. Bone Marrow
14.6.5.2.5. Others
14.6.5.3. Australia Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
14.6.5.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
14.6.5.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
14.6.5.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
14.6.5.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
14.6.5.3.5. Others
14.6.5.4. Australia Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.5.4.1. Disease Treatment and Tissue Regeneration
14.6.5.4.2. Clinical Research
14.6.5.4.3. Personalized Banking Applications
14.6.6. South
Korea
14.6.6.1. South Korea Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
14.6.6.1.1. Storage
14.6.6.1.2. Testing and Processing
14.6.6.1.3. Collection
14.6.6.2. South Korea Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
14.6.6.2.1. Umbilical Cord
14.6.6.2.2. Placenta
14.6.6.2.3. Amniotic Fluid
14.6.6.2.4. Bone Marrow
14.6.6.2.5. Others
14.6.6.3. South Korea Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
14.6.6.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
14.6.6.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
14.6.6.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
14.6.6.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
14.6.6.3.5. Others
14.6.6.4. South Korea Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.6.4.1. Disease Treatment and Tissue Regeneration
14.6.6.4.2. Clinical Research
14.6.6.4.3. Personalized Banking Applications
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
14.6.7.1.1. Storage
14.6.7.1.2. Testing and Processing
14.6.7.1.3. Collection
14.6.7.2. Southeast Asia Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
14.6.7.2.1. Umbilical Cord
14.6.7.2.2. Placenta
14.6.7.2.3. Amniotic Fluid
14.6.7.2.4. Bone Marrow
14.6.7.2.5. Others
14.6.7.3. Southeast Asia Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
14.6.7.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
14.6.7.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
14.6.7.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
14.6.7.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
14.6.7.3.5. Others
14.6.7.4. Southeast Asia Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.7.4.1. Disease Treatment and Tissue Regeneration
14.6.7.4.2. Clinical Research
14.6.7.4.3. Personalized Banking Applications
14.6.7.5. Southeast Asia Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Stem Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Service Type
14.6.8.1.1. Storage
14.6.8.1.2. Testing and Processing
14.6.8.1.3. Collection
14.6.8.2. Rest of Asia Pacific Stem Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Source
14.6.8.2.1. Umbilical Cord
14.6.8.2.2. Placenta
14.6.8.2.3. Amniotic Fluid
14.6.8.2.4. Bone Marrow
14.6.8.2.5. Others
14.6.8.3. Rest of Asia Pacific Stem Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Medical Condition
14.6.8.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
14.6.8.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
14.6.8.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
14.6.8.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
14.6.8.3.5. Others
14.6.8.4. Rest of Asia Pacific Stem Cell Banking Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.8.4.1. Disease Treatment and Tissue Regeneration
14.6.8.4.2. Clinical Research
14.6.8.4.3. Personalized Banking Applications
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Service Type
14.7.3. By
Source
14.7.4. By
Medical Condition
14.7.5. By
Application
15. Middle East and Africa Stem Cell Banking Market Analysis and
Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Middle
East and Africa Stem Cell Banking Market Revenue (US$ Mn)
15.2. Middle
East and Africa Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Service Type
15.2.1. Storage
15.2.2. Testing
and Processing
15.2.3. Collection
15.3. Middle
East and Africa Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Source
15.3.1. Umbilical
Cord
15.3.2. Placenta
15.3.3. Amniotic
Fluid
15.3.4. Bone
Marrow
15.3.5. Others
15.4. Middle
East and Africa Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Medical Condition
15.4.1. Cancer (Leukaemias,
Lymphomas, Etc.)
15.4.2. Non
Malignant Blood Disorders (Anaemias, Hereditary Bone Marrow Failure Syndromes,
Etc.)
15.4.3. Immune
Disorder (Severe Combined Immune Deficiency (SCID), Inherited Immune System
Disorders, etc.)
15.4.4. Metabolic
Disorders (Leukodystrophy Disorders, Mucopolysaccharidosis (MPS) Storage
Diseases, Etc.)
15.4.5. Others
15.5. Middle
East and Africa Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Application
15.5.1. Disease
Treatment and Tissue Regeneration
15.5.2. Clinical
Research
15.5.3. Personalized
Banking Applications
15.6. Middle
East and Africa Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By
Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
15.6.1.1.1. Storage
15.6.1.1.2. Testing and Processing
15.6.1.1.3. Collection
15.6.1.2. Saudi Arabia Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
15.6.1.2.1. Umbilical Cord
15.6.1.2.2. Placenta
15.6.1.2.3. Amniotic Fluid
15.6.1.2.4. Bone Marrow
15.6.1.2.5. Others
15.6.1.3. Saudi Arabia Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
15.6.1.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
15.6.1.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
15.6.1.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
15.6.1.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
15.6.1.3.5. Others
15.6.1.4. Saudi Arabia Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.1.4.1. Disease Treatment and Tissue Regeneration
15.6.1.4.2. Clinical Research
15.6.1.4.3. Personalized Banking Applications
15.6.2. UAE
15.6.2.1. UAE Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Service Type
15.6.2.1.1. Storage
15.6.2.1.2. Testing and Processing
15.6.2.1.3. Collection
15.6.2.2. UAE Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Source
15.6.2.2.1. Umbilical Cord
15.6.2.2.2. Placenta
15.6.2.2.3. Amniotic Fluid
15.6.2.2.4. Bone Marrow
15.6.2.2.5. Others
15.6.2.3. UAE Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Medical Condition
15.6.2.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
15.6.2.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
15.6.2.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
15.6.2.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
15.6.2.3.5. Others
15.6.2.4. UAE Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Application
15.6.2.4.1. Disease Treatment and Tissue Regeneration
15.6.2.4.2. Clinical Research
15.6.2.4.3. Personalized Banking Applications
15.6.3. Egypt
15.6.3.1. Egypt Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Service Type
15.6.3.1.1. Storage
15.6.3.1.2. Testing and Processing
15.6.3.1.3. Collection
15.6.3.2. Egypt Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Source
15.6.3.2.1. Umbilical Cord
15.6.3.2.2. Placenta
15.6.3.2.3. Amniotic Fluid
15.6.3.2.4. Bone Marrow
15.6.3.2.5. Others
15.6.3.3. Egypt Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Medical Condition
15.6.3.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
15.6.3.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone Marrow
Failure Syndromes, Etc.)
15.6.3.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
15.6.3.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
15.6.3.3.5. Others
15.6.3.4. Egypt Stem Cell Banking Market Revenue (US$ Mn) and Forecasts,
By Application
15.6.3.4.1. Disease Treatment and Tissue Regeneration
15.6.3.4.2. Clinical Research
15.6.3.4.3. Personalized Banking Applications
15.6.4. Kuwait
15.6.4.1. Kuwait Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
15.6.4.1.1. Storage
15.6.4.1.2. Testing and Processing
15.6.4.1.3. Collection
15.6.4.2. Kuwait Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
15.6.4.2.1. Umbilical Cord
15.6.4.2.2. Placenta
15.6.4.2.3. Amniotic Fluid
15.6.4.2.4. Bone Marrow
15.6.4.2.5. Others
15.6.4.3. Kuwait Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
15.6.4.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
15.6.4.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
15.6.4.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
15.6.4.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
15.6.4.3.5. Others
15.6.4.4. Kuwait Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.4.4.1. Disease Treatment and Tissue Regeneration
15.6.4.4.2. Clinical Research
15.6.4.4.3. Personalized Banking Applications
15.6.5. South
Africa
15.6.5.1. South Africa Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
15.6.5.1.1. Storage
15.6.5.1.2. Testing and Processing
15.6.5.1.3. Collection
15.6.5.2. South Africa Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
15.6.5.2.1. Umbilical Cord
15.6.5.2.2. Placenta
15.6.5.2.3. Amniotic Fluid
15.6.5.2.4. Bone Marrow
15.6.5.2.5. Others
15.6.5.3. South Africa Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
15.6.5.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
15.6.5.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
15.6.5.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
15.6.5.3.4. Metabolic Disorders (Leukodystrophy Disorders, Mucopolysaccharidosis
(MPS) Storage Diseases, Etc.)
15.6.5.3.5. Others
15.6.5.4. South Africa Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.5.4.1. Disease Treatment and Tissue Regeneration
15.6.5.4.2. Clinical Research
15.6.5.4.3. Personalized Banking Applications
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Stem Cell Banking Market
Revenue (US$ Mn) and Forecasts, By Service Type
15.6.6.1.1. Storage
15.6.6.1.2. Testing and Processing
15.6.6.1.3. Collection
15.6.6.2. Rest of Middle East & Africa Stem Cell Banking Market
Revenue (US$ Mn) and Forecasts, By Source
15.6.6.2.1. Umbilical Cord
15.6.6.2.2. Placenta
15.6.6.2.3. Amniotic Fluid
15.6.6.2.4. Bone Marrow
15.6.6.2.5. Others
15.6.6.3. Rest of Middle East & Africa Stem Cell Banking Market
Revenue (US$ Mn) and Forecasts, By Medical Condition
15.6.6.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
15.6.6.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
15.6.6.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
15.6.6.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
15.6.6.3.5. Others
15.6.6.4. Rest of Middle East & Africa Stem Cell Banking Market
Revenue (US$ Mn) and Forecasts, By Application
15.6.6.4.1. Disease Treatment and Tissue Regeneration
15.6.6.4.2. Clinical Research
15.6.6.4.3. Personalized Banking Applications
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By
Service Type
15.7.3. By
Source
15.7.4. By
Medical Condition
15.7.5. By
Application
16. Latin America Stem Cell Banking Market Analysis and
Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Latin
America Stem Cell Banking Market Revenue (US$ Mn)
16.2. Latin
America Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Service
Type
16.2.1. Storage
16.2.2. Testing
and Processing
16.2.3. Collection
16.3. Latin
America Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Source
16.3.1. Umbilical
Cord
16.3.2. Placenta
16.3.3. Amniotic
Fluid
16.3.4. Bone
Marrow
16.3.5. Others
16.4. Latin
America Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Medical
Condition
16.4.1. Cancer
(Leukaemias, Lymphomas, Etc.)
16.4.2. Non
Malignant Blood Disorders (Anaemias, Hereditary Bone Marrow Failure Syndromes,
Etc.)
16.4.3. Immune
Disorder (Severe Combined Immune Deficiency (SCID), Inherited Immune System
Disorders, etc.)
16.4.4. Metabolic
Disorders (Leukodystrophy Disorders, Mucopolysaccharidosis (MPS) Storage
Diseases, Etc.)
16.4.5. Others
16.5. Latin
America Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Application
16.5.1. Disease
Treatment and Tissue Regeneration
16.5.2. Clinical
Research
16.5.3. Personalized
Banking Applications
16.6. Latin
America Stem Cell Banking Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
16.6.1.1.1. Storage
16.6.1.1.2. Testing and Processing
16.6.1.1.3. Collection
16.6.1.2. Brazil Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
16.6.1.2.1. Umbilical Cord
16.6.1.2.2. Placenta
16.6.1.2.3. Amniotic Fluid
16.6.1.2.4. Bone Marrow
16.6.1.2.5. Others
16.6.1.3. Brazil Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
16.6.1.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
16.6.1.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
16.6.1.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
16.6.1.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
16.6.1.3.5. Others
16.6.1.4. Brazil Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
16.6.1.4.1. Disease Treatment and Tissue Regeneration
16.6.1.4.2. Clinical Research
16.6.1.4.3. Personalized Banking Applications
16.6.2. Argentina
16.6.2.1. Argentina Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Service Type
16.6.2.1.1. Storage
16.6.2.1.2. Testing and Processing
16.6.2.1.3. Collection
16.6.2.2. Argentina Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Source
16.6.2.2.1. Umbilical Cord
16.6.2.2.2. Placenta
16.6.2.2.3. Amniotic Fluid
16.6.2.2.4. Bone Marrow
16.6.2.2.5. Others
16.6.2.3. Argentina Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Medical Condition
16.6.2.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
16.6.2.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
16.6.2.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
16.6.2.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
16.6.2.3.5. Others
16.6.2.4. Argentina Stem Cell Banking Market Revenue (US$ Mn) and
Forecasts, By Application
16.6.2.4.1. Disease Treatment and Tissue Regeneration
16.6.2.4.2. Clinical Research
16.6.2.4.3. Personalized Banking Applications
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Stem Cell Banking Market Revenue (US$
Mn) and Forecasts, By Service Type
16.6.3.1.1. Storage
16.6.3.1.2. Testing and Processing
16.6.3.1.3. Collection
16.6.3.2. Rest of Latin America Stem Cell Banking Market Revenue (US$
Mn) and Forecasts, By Source
16.6.3.2.1. Umbilical Cord
16.6.3.2.2. Placenta
16.6.3.2.3. Amniotic Fluid
16.6.3.2.4. Bone Marrow
16.6.3.2.5. Others
16.6.3.3. Rest of Latin America Stem Cell Banking Market Revenue (US$
Mn) and Forecasts, By Medical Condition
16.6.3.3.1. Cancer (Leukaemias, Lymphomas, Etc.)
16.6.3.3.2. Non Malignant Blood Disorders (Anaemias, Hereditary Bone
Marrow Failure Syndromes, Etc.)
16.6.3.3.3. Immune Disorder (Severe Combined Immune Deficiency (SCID),
Inherited Immune System Disorders, etc.)
16.6.3.3.4. Metabolic Disorders (Leukodystrophy Disorders,
Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)
16.6.3.3.5. Others
16.6.3.4. Rest of Latin America Stem Cell Banking Market Revenue (US$
Mn) and Forecasts, By Application
16.6.3.4.1. Disease Treatment and Tissue Regeneration
16.6.3.4.2. Clinical Research
16.6.3.4.3. Personalized Banking Applications
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Service Type
16.7.3. By
Source
16.7.4. By
Medical Condition
16.7.5. By
Application
17. Competitive Benchmarking
17.1. Market
Share Analysis, 2020
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player Profiles
18.1. CBR Systems, Inc.
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. Cell Care
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business
Strategies
18.3. CHA Biotech
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. CordBank New Zealand
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. Cordlife
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. Cryo-Cell
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. CryoHoldco
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. Cryoviva India
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. CSG-BIO
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Global Cord Blood Corporation.
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT Analysis
18.10.7. Business
Strategies
18.11. LifeCell International Pvt.
Ltd.
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business
Strategies
18.12. ReeLabs Pvt. Ltd.
18.12.1. Company
Details
18.12.2. Company
Overview
18.12.3. Product
Offerings
18.12.4. Key
Developments
18.12.5. Financial
Analysis
18.12.6. SWOT
Analysis
18.12.7. Business
Strategies
18.13. Regrow Biosciences Pvt Ltd.
18.13.1. Company
Details
18.13.2. Company
Overview
18.13.3. Product
Offerings
18.13.4. Key
Developments
18.13.5. Financial
Analysis
18.13.6. SWOT
Analysis
18.13.7. Business
Strategies
18.14. Smart Cells International Ltd.
18.14.1. Company
Details
18.14.2. Company
Overview
18.14.3. Product
Offerings
18.14.4. Key
Developments
18.14.5. Financial
Analysis
18.14.6. SWOT
Analysis
18.14.7. Business
Strategies
18.15. Stem Med Pte Ltd
18.15.1. Company
Details
18.15.2. Company
Overview
18.15.3. Product
Offerings
18.15.4. Key
Developments
18.15.5. Financial
Analysis
18.15.6. SWOT
Analysis
18.15.7. Business
Strategies
18.16. StemCyte
18.16.1. Company
Details
18.16.2. Company
Overview
18.16.3. Product
Offerings
18.16.4. Key
Developments
18.16.5. Financial
Analysis
18.16.6. SWOT
Analysis
18.16.7. Business
Strategies
18.17. ViaCord
18.17.1. Company
Details
18.17.2. Company
Overview
18.17.3. Product
Offerings
18.17.4. Key
Developments
18.17.5. Financial
Analysis
18.17.6. SWOT Analysis
18.17.7. Business
Strategies
18.18. Vita 34 Inc.
18.18.1. Company
Details
18.18.2. Company
Overview
18.18.3. Product
Offerings
18.18.4. Key
Developments
18.18.5. Financial
Analysis
18.18.6. SWOT
Analysis
18.18.7. Business
Strategies
18.19. Other
Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.